These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9064908)

  • 21. Genetic adjuvant therapy for pancreatic cancer and other solid tumours.
    Bagley KC
    Gut; 2008 Mar; 57(3):289-91. PubMed ID: 18268052
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. beta-Glycosphingolipids as immune modulators.
    Adar T; Ilan Y
    J Immunotoxicol; 2008 Apr; 5(2):209-20. PubMed ID: 18569392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunomodulation in oncology].
    Pérez Cuadrado S
    Rev Clin Esp; 1992 Sep; 191(4):177-80. PubMed ID: 1439036
    [No Abstract]   [Full Text] [Related]  

  • 25. Biological response modifiers.
    Clark JW
    Cancer Chemother Biol Response Modif; 1988; 10():434-59. PubMed ID: 3079394
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunomodulation of cancer with activated cytotoxic leukocytes.
    Stevenson HC; Stevenson GW
    Prog Clin Biol Res; 1990; 337():435-8. PubMed ID: 2191333
    [No Abstract]   [Full Text] [Related]  

  • 27. Gene manipulation in the induction of anti-tumour immunity.
    O'Donnell D; Patel P; Reis e Sousa C
    Gene Ther; 1999 Nov; 6(11):1796-7. PubMed ID: 10602374
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeting cancer therapy.
    Begent RH
    Br J Cancer; 1999 Jul; 80 Suppl 1():104-9. PubMed ID: 10466768
    [No Abstract]   [Full Text] [Related]  

  • 29. Protein toxins: intracellular trafficking for targeted therapy.
    Johannes L; Decaudin D
    Gene Ther; 2005 Sep; 12(18):1360-8. PubMed ID: 15902276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hematopoietic stem cell transplant as a platform for tumor immunotherapy.
    Fuchs EJ; Whartenby KA
    Curr Opin Mol Ther; 2004 Feb; 6(1):48-53. PubMed ID: 15011781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens.
    Kuroki M; Shibaguchi H; Imakiire T; Uno K; Shirota K; Higuchi T; Shitama T; Yamada H; Hirose Y; Nagata A; Kuroki M
    Anticancer Res; 2003; 23(6a):4377-81. PubMed ID: 14666724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cells and cytokines in immunotherapy and gene therapy of cancer.
    Pawelec G; Rees RC; Kiessling R; Madrigal A; Dodi A; Baxevanis C; Gambacorti-Passerini C; Masucci G; Zeuthen J
    Crit Rev Oncog; 1999; 10(1-2):83-127. PubMed ID: 10327211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prospects for improving antibody therapy for carcinoma].
    Liu XY
    Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1145-6. PubMed ID: 15387972
    [No Abstract]   [Full Text] [Related]  

  • 35. Development of immunotherapeutic strategies for the treatment of malignant neoplasms.
    Talmadge JE
    Biotherapy; 1992; 4(3):215-36. PubMed ID: 1599805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy.
    Wojtowicz-Praga S
    J Immunother; 1997 May; 20(3):165-77. PubMed ID: 9181454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
    Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
    Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological response modifiers.
    Clark JW
    Cancer Chemother Biol Response Modif; 1990; 11():235-64. PubMed ID: 2121207
    [No Abstract]   [Full Text] [Related]  

  • 39. Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.
    Dang Y; Disis ML
    Ann N Y Acad Sci; 2009 Sep; 1174():81-7. PubMed ID: 19769740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of activated natural killer cells for tumor immunotherapy in mouse and human.
    Basse PH; Whiteside TL; Herberman RB
    Methods Mol Biol; 2000; 121():81-94. PubMed ID: 10818719
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.